Lobe Sciences

Lobe Sciences

Private Company
Public Company
Subsidiary of
Clinical Trials, R&D

About

Lobe Sciences is a life sciences company focused on psychedelic medicines and specializing in the treatment of PTSD and mTBI through microdosing methodology. Through the acquisition of Eleusian Biosciences, the company is engaged in research and development of using psychedelic compounds and innovative devices and delivery mechanisms to improve mental health and wellness. They have a strong IP platform with several pending patents for drug compounds and delivery devices.


Lobe listed on the CSE through a reverse takeover of Green Star Biosciences and is currently trading under the symbol 'LOBE.' The company also trades under the symbol “GTSIF” on the OTCQX.

Traction

- 5 patent applications, including three on novel drug compounds, focusing on unique formulations of NAC combined with psilocybin or MDMA, and two on unique delivery devices and delivery methods.


- Developed proof-of-concept prototype of its proprietary nasal mist device.

- Patent pending on drug formulation designed to promote memory odour imprint pairing.


- Developing virtual reality headset combined with nasal mist device in order establish guided meditations and assisted therapy sessions in tandem with micro dosing treatment.

Team

Phillip J. Young, Chief Executive Officer & Director

  • 20 years experience as CEO and Director of public companies with direct experience in M&A transactions, generating more than $900M in acquisitions.
  • Endocrine and cardiovascular product launch sales and marketing manager for Genentech inc.

Maghsoud Dariani, Chief Science Officer

  • Extensive experience in the discovery and development of novel therapeutics into clinical stage and securing FDA approval.
  • Previous president of Focus Pharmaceuticals where he led sale of the company.
  • Previous VP of  Celegene Corporation during the development of FDA approved Focalin & Focalin RX.

Dr. Mark A. Geyer, PHD, Science Advisor

  • Distinguished professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego.
  • Published over 470 peer-reviewed papers, many focused on the mechanism and effects of psychedelics and psychostimulants.

Benjamin Kelmendi, MD, Scientific Advisor

  • Psychiatrist and Associate Professor in the Department of Psychiatry at Yale University School of Medicine.
  • Co-founder of the Yale Psychedelic Science Group.
  • Leads a research program investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD.
  • Exploring the effects of MDMA on brain activation and neural network organization in PTSD